Gilead Sciences, Inc. (GILD) operating KPIs
GILDNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026Score 11/30105% above fair value
$170.68+5.07 (+3.06%)
Close on Oct 30, 2026Market cap $211.64BP/E –Yield 1.85%
Gilead Sciences total gross-to-net (GTN) deductions ($M) ($M)
Form 10-K MD&A Gross-to-Net Deductions
Latest, FY2025
19,953
Period ended Dec 31, 2025
Change on a year earlier
+12.2%
17,776 in FY2024
History
2 years
Since FY2024
Sources
1
Form 10-K (gild-20251231.htm, filed 2026-02-24)
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Total gross-to-net (GTN) deductions ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 19,953 | +12.2% | Form 10-K (gild-20251231.htm, filed 2026-02-24) ↗ |
| FY2024 | Dec 31, 2024 | 17,776 | – | Form 10-K (gild-20251231.htm, filed 2026-02-24) ↗ |
Cite this data
StockData. (2026). Gilead Sciences Total gross-to-net (GTN) deductions ($M) ($M), annual FY2024–FY2025 [Data set]. Compiled from Gilead Sciences SEC filings and investor materials. https://stockdatahq.com/stocks/gild/kpis/gtn_deductions_tot
See every metric in the Gilead Sciences KPI table. Data updated Oct 29, 2026.